Syndax Pharmaceuticals (SNDX) Debt to Equity (2020 - 2024)
Syndax Pharmaceuticals has reported Debt to Equity over the past 5 years, most recently at $1.19 for Q4 2024.
- Quarterly results put Debt to Equity at $1.19 for Q4 2024, changed N/A from a year ago — trailing twelve months through Dec 2024 was $1.19 (changed N/A YoY), and the annual figure for FY2024 was $1.19, changed.
- Debt to Equity for Q4 2024 was $1.19 at Syndax Pharmaceuticals, up from $0.06 in the prior quarter.
- Over the last five years, Debt to Equity for SNDX hit a ceiling of $1.19 in Q4 2024 and a floor of $0.05 in Q4 2021.
- Median Debt to Equity over the past 4 years was $0.09 (2021), compared with a mean of $0.22.
- Peak annual rise in Debt to Equity hit 29.61% in 2021, while the deepest fall reached 76.03% in 2021.
- Syndax Pharmaceuticals' Debt to Equity stood at $0.08 in 2020, then tumbled by 38.36% to $0.05 in 2021, then rose by 13.52% to $0.06 in 2022, then soared by 2036.64% to $1.19 in 2024.
- The last three reported values for Debt to Equity were $1.19 (Q4 2024), $0.06 (Q2 2022), and $0.05 (Q1 2022) per Business Quant data.